With just weeks to go in its legislative session, Missouri lawmakers are making progress on two different 340B anti-discrimination bills. Last week, a key Senate committee approved SB 26, comprehensive legislation with two key priorities: prohibiting drug manufacturers from placing restrictions on 340B pricing in the contract pharmacy setting and prohibiting pharmacy benefit managers from alleged discriminatory reimbursement practices.
SB 26, introduced by Missouri state Senator Justin Brown (R), was approved by the Senate Banking and Insurance Committee on April 12th. Brown’s bill is modeled on the first-of-its kind law passed in Arkansas in 2021. The Arkansas law is currently being challenged by the drug industry trade group Pharmaceutical Research and Manufacturers of America in federal appeals court in St. Louis.
With just weeks to go in its legislative session, Missouri lawmakers are making progress on two different 340B anti-discrimination bills. Last week, a key Senate committee approved SB 26, comprehensive legislation with two key priorities: prohibiting drug manufacturers from placing […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
